HitGen, Inc.

HitGen, Inc. faced a decline on August 21, 2026, despite a strong long-term performance, including a 62.15% increase over the past year. The company reported a net profit growth of 114.98% and a robust operating cash flow, maintaining a significant market capitalization within the Pharmaceuticals & Biotechnology sector.

HitGen, Inc. has shown significant growth, with a 5.17% increase today and a remarkable 29.08% rise over the past week. The company reported a 114.98% net profit growth in September and achieved its highest operating cash flow. Its market capitalization stands at CNY 14,577 million.

HitGen, Inc. has shown remarkable stock performance, gaining 7.28% on August 10, 2026, and achieving a 61.55% increase over the past year. The company reported significant financial growth, including a net profit rise of 114.98% and record operating cash flow of CNY 204.8 million.

HitGen, Inc. faced a decline on July 28, 2026, amidst market volatility, yet has demonstrated strong year-to-date performance, outpacing the China Shanghai Composite. The company reported significant net profit growth and achieved high operating cash flow, indicating a robust financial foundation despite short-term challenges.

HitGen, Inc. faced a significant stock price decline today, reaching an intraday low. Despite this, the company has shown mixed performance, with notable annual gains and strong financial fundamentals, including substantial net profit growth and healthy operating cash flow, indicating resilience in its overall financial health.

HitGen, Inc. faced a notable stock decline today, reaching an intraday low. However, the company has demonstrated strong long-term performance, with a significant annual increase and impressive financial metrics, including substantial net profit growth and high operating cash flow, maintaining a solid market presence.

HitGen, Inc. has shown strong stock performance, gaining 7.23% today and achieving a 10.68% increase over the past week. The company reported a 114.98% growth in net profit and a record operating cash flow of CNY 204.8 million, reinforcing its market position with a capitalization of CNY 10,782 million.

HitGen, Inc. has shown impressive stock performance, with a notable increase over the past week and a substantial annual gain. The company reported significant growth in net profit and operating cash flow, highlighting its strong financial health and resilience in the Pharmaceuticals & Biotechnology sector.

HitGen, Inc. has experienced notable stock performance, achieving a significant increase today and impressive growth over the past week and year. The company reported strong financial metrics, including substantial net profit growth and high operating cash flow, reinforcing its status in the Pharmaceuticals & Biotechnology sector.

HitGen, Inc. experienced a decline in stock value on June 1, 2026, amid a slight decrease in the China Shanghai Composite index. Despite recent challenges, the company has shown strong long-term performance, with significant profit growth and robust operational efficiency, maintaining a notable market capitalization.

HitGen, Inc. faced a decline on May 28, 2026, amid a mixed market, despite a strong long-term performance with a 96.9% increase over the past year. The company reported significant financial growth, including a net profit rise of 114.98% and a market capitalization of CNY 11,980 million.

HitGen, Inc. has experienced notable stock performance, reaching an intraday high of CNY 32.34. The company reported impressive financial metrics, including a 114.98% net profit growth and a significant increase in operating cash flow. Over the past year, HitGen has achieved remarkable growth, outperforming broader market indices.

HitGen, Inc. has experienced notable stock performance, contrasting with the decline of the China Shanghai Composite. The company reported significant growth in net profit and operating cash flow, alongside a strong market capitalization. Its impressive year-over-year gains highlight its resilience in the biotechnology sector.

HitGen, Inc. has seen a significant rise in its stock price, contrasting with the broader market's performance. The company reported impressive financial metrics, including a substantial net profit growth and strong operating cash flow. Over the past year, HitGen has outperformed the Shanghai Composite, showcasing its resilience in the pharmaceutical sector.

HitGen, Inc. faced a challenging trading day with a significant stock price decline. Over the past week and month, the company has seen notable downturns, yet it has shown strong annual growth. Financially, HitGen reported impressive increases in net profit and operating cash flow, highlighting its resilience in the market.

HitGen, Inc. faced a significant stock decline on March 3, 2026, with a notable drop in performance metrics over the past week and month. Despite recent volatility, the company reported strong financial results, including substantial net profit growth, while its long-term performance remains challenging.

HitGen, Inc. experienced a decline on February 24, 2026, amid a broader market downturn. Over the past month, the company has faced a significant drop, although it has shown strong annual growth. Financially, HitGen reported substantial net profit growth and maintains a solid market capitalization.